A multicenter, open-label phase Ib/II study of cadonilimab (anti PD-1 and CTLA-4 bispecific antibody) monotherapy in previously treated advanced non–small-cell lung cancer (AK104-202 study)

Yuanyuan Zhao, Yuxiang Ma, Yun Fan, Jianya Zhou, Nong Yang, Qitao Yu, Wu Zhuang, Weifeng Song, Zhongmin Maxwell Wang, Baiyong Li, Yu Xia, Hongyun Zhao, Li Zhang